Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback